Novartis

No single number decides. Layers can disagree — that's the point. New to this? →

The platform's own early signals for this company — hard-to-fake, and where one preceded a real raise, the measured lead.

• TLS certificate transparency 10 signals · latest 2020-04-20

See the full track record →

• bullish endorsement Demis Hassabis

  we have great partnerships with Eli Lilly. I think you had the CEO speaking earlier, and Novartis, which are fantastic, and our own internal drug programs.

• bullish assessment Demis Hassabis

  I think you're going to see two things, which is the sort of democratization of these tools for everybody to just use and create with without having to learn incredibly complex UXs and UIs like we had to do in the past. But on the other hand, I think we're also collaborating with filmmakers and top creators and artists. So, they're helping us design what these new tools should be. What features would they want? People like the director, Darren Aronofsky, who's a good friend of mine, an amazing d

• bullish assessment Demis Hassabis

  with Nano Banana, what's amazing about it is that it's an image generator. It's state-of-the-art and best-in-class.

• bullish assessment Demis Hassabis

  No, I mean, we're not seeing that internally. And we're still seeing a huge rate of progress.

• bullish prediction Demis Hassabis

  So I think that we are maybe, you know, I would say sort of five to 10 years away from having an AGI system that's capable of doing those things.